Legend BioTech shares are trading higher. Scotiabank maintained a Sector Outperform rating on the stock and raised its price target from $70 to $76.
Portfolio Pulse from Benzinga Newsdesk
Legend BioTech shares are trading higher after Scotiabank maintained a Sector Outperform rating and raised its price target from $70 to $76.

August 12, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend BioTech shares are trading higher following Scotiabank's decision to maintain a Sector Outperform rating and increase the price target from $70 to $76.
The increase in price target and maintained positive rating from a reputable financial institution like Scotiabank is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100